Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
In late September 2023, the FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease (LOPD) in adults who weigh more than 40 kg and are not improving on their current enzyme replacement therapy. The approval for Pombiliti + Opfolda in the United States is a huge boost and provides a significant commercial opportunity for Amicus in 2024. This could have been one of the factors driving the stock's rise in the said time frame. Earlier in 2023, Pombiliti + Opfolda was approved in Europe, including the United Kingdom, for treating LOPD in adults. Image Source: Zacks Investment Research Amicus' lead drug, Galafold (migalastat), is the first and only approved oral medicine for patients living with Fabry disease, having amenable genetic variants. The drug has shown solid uptake since its launch. Sales of Galafold have been rising consistently over the past years. In the first nine months of 2023, the drug generated sales worth $281.2 million,
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Become Profitable? [Yahoo! Finance]Yahoo! Finance
- Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) ReportGlobeNewswire
- Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at JPMorgan Chase & Co. from $21.00 to $19.00. They now have an "overweight" rating on the stock.MarketBeat
FOLD
Earnings
- 2/28/24 - Beat
FOLD
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEF
- 4/24/24 - Form DEFA14A
- FOLD's page on the SEC website